Want to see SE:GETI.B full AI Analyst Report?
Top Page
Getinge
(GETI.B)
Select Model
Select Model
Rating:67Neutral
Price Target:
kr289.00
▲(18.78% Upside)
Action:Reiterated
Date:10/23/26
Overall score reflects solid recovering fundamentals (improving profitability and cash generation with manageable leverage) tempered by a stretched technical setup (overbought signals despite a strong uptrend) and a relatively high P/E with only modest dividend support.
Positive Factors
Recurring Installed-Base Revenue
Revenue is diversified across capital equipment, service contracts, and consumables, while the installed base supports repeat demand over long equipment lifecycles. This mix can make customer relationships more durable and reduce reliance on any single purchase cycle.
Negative Factors
Flat Revenue Trend
Limited revenue growth suggests that the recent earnings recovery is not yet being driven by broad top-line expansion. Without stronger demand or market share gains, Getinge may have less operating leverage and fewer opportunities to compound earnings over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Installed-Base Revenue
Revenue is diversified across capital equipment, service contracts, and consumables, while the installed base supports repeat demand over long equipment lifecycles. This mix can make customer relationships more durable and reduce reliance on any single purchase cycle.
Read all positive factors
Getinge (GETI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr74.06B
Dividend Yield1.75%
Average Volume (3M)621.24K
Price to Earnings (P/E)26.2
Beta (1Y)0.81
Revenue Growth-3.90%
EPS Growth37.73%
CountrySE
Employees11,847
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)10.39
Shares Outstanding254,152,370
10 Day Avg. Volume584,417
30 Day Avg. Volume621,243
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.03
Price to Sales (P/S)1.70
P/FCF Ratio22.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr234.33Price Target Upside-3.69% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)13.28
Revenue Forecast (FY)kr35.37B
Getinge Business Overview & Revenue Model
Company Description
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, int...
How the Company Makes Money
Getinge makes money primarily by selling medical technology and life-science equipment, complemented by recurring revenue from services and consumables tied to its installed base.
1) Capital equipment sales (one-time/less frequent purchases): A s...
Getinge Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
70
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.46B | 34.97B | 34.76B | 31.83B | 28.29B | 27.05B |
| Gross Profit | 16.33B | 15.54B | 16.15B | 14.49B | 13.43B | 13.58B |
| EBITDA | 6.80B | 6.04B | 5.31B | 5.93B | 5.70B | 6.15B |
| Net Income | 2.83B | 2.26B | 1.64B | 2.41B | 2.49B | 2.97B |
Balance Sheet | ||||||
| Total Assets | 59.60B | 56.51B | 63.92B | 53.59B | 52.03B | 46.05B |
| Cash, Cash Equivalents and Short-Term Investments | 3.16B | 3.40B | 2.96B | 2.73B | 5.68B | 4.08B |
| Total Debt | 11.23B | 10.88B | 10.73B | 8.08B | 5.82B | 4.31B |
| Total Liabilities | 26.89B | 27.01B | 30.71B | 23.18B | 21.58B | 20.88B |
| Stockholders Equity | 32.65B | 29.43B | 33.01B | 30.17B | 30.04B | 24.75B |
Cash Flow | ||||||
| Free Cash Flow | 4.32B | 2.63B | 3.27B | 1.60B | 2.23B | 5.63B |
| Operating Cash Flow | 5.52B | 3.95B | 4.58B | 2.96B | 3.37B | 6.56B |
| Investing Cash Flow | -2.70B | -2.96B | -4.55B | -6.54B | -1.47B | -1.33B |
| Financing Cash Flow | -2.49B | -765.00M | 504.00M | 511.00M | -500.00M | -7.24B |
Getinge Technical Analysis
Positive
243.30
Price Trends
248.30
Positive
232.47
Positive
212.45
Positive
Market Momentum
6.29
Negative
78.90
Negative
92.06
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 243.3 is below the 20-day moving average (MA) of 256.87, below the 50-day MA of 248.30, and above the 200-day MA of 212.45, indicating a bullish trend. The MACD of 6.29 indicates Negative momentum. The RSI at 78.90 is Negative, neither overbought nor oversold. The STOCH value of 92.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.
Getinge Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr21.00B | 77.19 | 29.00% | ― | 25.20% | 79.34% | |
74 Outperform | kr66.11B | 103.61 | 30.26% | 0.39% | 13.94% | 5.70% | |
67 Neutral | kr74.06B | 26.17 | 9.13% | 1.75% | -3.90% | 37.73% | |
64 Neutral | kr6.45B | 50.07 | 5.89% | ― | 17.83% | 330.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | kr564.21M | 89.44 | 1.93% | ― | -0.51% | ― | |
51 Neutral | kr893.04M | -25.88 | -3.88% | ― | 0.42% | 15.03% |
* General Sector Average
SE:GETI.B
Getinge
271.90
52.39
23.87%
SE:BONEX
BONESUPPORT HOLDING AB
318.80
94.00
41.81%
SE:XVIVO
Xvivo Perfusion AB
204.80
13.50
7.06%
SE:BACTI.B
Bactiguard Holding AB
16.10
-0.50
-3.01%
SE:SECT.B
Sectra AB Class B
338.80
32.64
10.66%
SE:SEDANA
Sedana Medical AB
8.99
-1.27
-12.38%
Getinge Corporate Events
Getinge lifts margins and cash flow as new critical-care products roll out
Oct 21, 2026
Getinge reported organic growth in net sales and order intake in the third quarter of 2026, with Acute Care Therapies leading sales and Surgical Workflows posting stable operating room demand, while parts of Life Science continued to face subdued ...
Getinge appoints Nomination Committee ahead of 2027 AGM
Oct 15, 2026
Getinge has appointed its Nomination Committee ahead of the 2027 Annual General Meeting in line with its governance principles, naming Chairman of the Board Johan Malmquist and representatives from major shareholders Carl Bennet AB, AMF Pension F...
Getinge’s Life Science President Eric Honroth to Step Down
Oct 7, 2026
Getinge AB announced that Eric Honroth will step down as President Life Science and leave the executive management team to pursue an external opportunity, marking a notable leadership change in one of the group’s key business areas. The comp...
Getinge Schedules Q3 2026 Report Release and Investor Call
Oct 7, 2026
Swedish medtech group Getinge has announced that it will publish its third-quarter 2026 financial report on October 21 at 08:00 a.m. CEST, followed by a conference call at 10:00 a.m. CEST led by President and CEO Mattias Perjos and CFO Agneta Palm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.